GSK3B and type 2 diabetes mellitus: Several researchers had investigated that AKT represses GSK-3β activity via phosphorylating GSK-3β (ser-9) in a mouse model of T2DM and high glucose conditions, promoting podocyte apoptosis, inhibiting autophagy, and aggravating renal damage [18–20].